2015
Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations
Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations. CNS Drugs 2015, 29: 465-486. PMID: 26142224, DOI: 10.1007/s40263-015-0255-x.Peer-Reviewed Original ResearchConceptsOpioid-induced hyperalgesiaClinical treatmentChronic painEfficacious treatment regimenTreatment of painOpioid-dependent individualsOpioid-related overdosesAminobutyric acid receptorsDeleterious profileProspective adjuvantOpioid prescriptionsSevere painOpioid analgesicsTreatment regimenNeuroimmune systemPainful stimuliSide effectsLong-term exposurePainAcid receptorsOpioidsClinical usePotential modulatorsHyperalgesiaParadoxical state
2013
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski E, Jane J, O’Brien E, Edens E, Arnaout B, Kerfoot K, Keegan K, Weiner J, Russo M, Petrakis I. Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. Journal Of Dual Diagnosis 2013, 9: 301-310. DOI: 10.1080/15504263.2013.835163.Peer-Reviewed Original ResearchDepressive symptomsAlcohol dependenceDual diagnosisRates of smokingMain outcome variablesSymptoms of depressionTreatment of peopleTreatment trialsComorbid depressionMecamylamineSide effectsNonsmokersSmokingSymptomsOutcome variablesBest treatmentDrinking outcomesDepressionPlaceboSmokersFurther studiesSignificant differencesDiagnosisParticipantsTreatment